June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Atypical Pathogens Observed in Recent Clinical Studies of Bacterial Conjunctivitis
Author Affiliations & Notes
  • Lynne Gearinger
    Microbiology and Sterilization Sciences, Bausch & Lomb, Inc, Rochester, NY
  • Christine Sanfilippo
    Microbiology and Sterilization Sciences, Bausch & Lomb, Inc, Rochester, NY
  • Lening Zhang
    Global Clinical Operations, Bausch & Lomb, Inc, Rochester, NY
  • Wolfgang Haas
    Microbiology and Sterilization Sciences, Bausch & Lomb, Inc, Rochester, NY
  • Timothy Comstock
    Global Medical Affairs, Bausch & Lomb, Inc, Rochester, NY
  • Timothy Morris
    Microbiology and Sterilization Sciences, Bausch & Lomb, Inc, Rochester, NY
  • Footnotes
    Commercial Relationships Lynne Gearinger, Bausch & Lomb, Inc. (E); Christine Sanfilippo, Bausch & Lomb, Inc. (E); Lening Zhang, Bausch + Lomb (E); Wolfgang Haas, Bausch & Lomb, Inc. (E); Timothy Comstock, Bausch & Lomb Incorporated (E); Timothy Morris, Bausch & Lomb, Inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5450. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lynne Gearinger, Christine Sanfilippo, Lening Zhang, Wolfgang Haas, Timothy Comstock, Timothy Morris; Atypical Pathogens Observed in Recent Clinical Studies of Bacterial Conjunctivitis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5450.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To compare prevalence and distribution of ocular pathogens encountered during recent (2009-2011) versus older (2004-2007) bacterial conjunctivitis clinical studies of besifloxacin ophthalmic suspension, 0.6%.

 
Methods
 

Pathogens recovered across five multicenter, randomized, double-masked, clinical studies evaluating besifloxacin were evaluated. A total of 2,348 baseline isolates from 3,379 patients were collected, of which 1,324 isolates were recovered in 2004-2007 and 1,024 in 2009-2011. Recovered isolates across all treatment groups were evaluated for baseline frequency, microbial eradication, and antimicrobial susceptibility profiles.

 
Results
 

Of interest, 15 new bacterial conjunctivitis pathogens, not recovered from study eyes between 2004-2007, were isolated in the later studies, including the potentially emerging pathogens Dolosigranulum pigrum (n=26) and Corynebacterium accolens (n=5). The 5 most frequently isolated species or taxomic groups remained the predominant bacterial conjunctivitis pathogens across all five besifloxacin studies. Microbial eradication rates of pathogens isolated in besifloxacin treated subjects in the more recent studies included 100% eradication of D. pigrum (14/14), Acinetobacter calcoaceticus/baumannii complex (3/3), and Elizabethkingia meningoseptica (2/2).

 
Conclusions
 

The most prevalent bacterial conjunctivitis pathogens have remained consistent across clinical trials over a seven year period; however, additional pathogens have emerged as causative agents of bacterial conjunctivitis. This may be due to improved methods for the identification of bacterial isolates or changes in human or bacterial ecology that promote the spreading of these species to the ocular surface. Eye care practitioners should be aware of these atypical pathogens when considering appropriate options for empiric treatment of bacterial conjunctivitis.

  
Keywords: 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 475 conjunctivitis • 593 microbial pathogenesis: clinical studies  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×